Search Results for “cancer” – Page 140 – media

Two Approvals for AstraZeneca in Japan

The immunotherapy drug was approved for lung cancer patients with no chance for surgery whose cancer had not yet spread to other parts of the body.
- Source: Reuters
- 980
- July 3, 2018
breast cancer Japan lung cancer New Approvals
Luspatercept Passes Phase 3 Clinical Trial for Rare Blood Disease

Acceleron Pharma and its partner Celgene have revealed that luspatercept hit its primary and secondary endpoints in phase 3 clinical trial of patients affected with chronic anemia associated with a rare blood disease.
- Source: FierceBiotech
- 655
- July 3, 2018
blood cancer Clinical Trial
PharmaAsia Recap

Recent news regarding pharma companies in Asia
- Source: FiercePharma
- 729
- July 3, 2018
Asia Market Views pharmaceutical company
NBE Therapeutics Receives $20 million in Series B by Novo Holdings

Switzerland-based NBE Therapeutics AG, a biopharmaceutical company, announced a $20 million extension of series B funding led by Novo Holdings. Earlier in the series B funding round, the company had received $20 million, bringing the total funding to $40 million. The Swiss startup will use the new funding for the testing of the anti-ROR1 antibody-drug conjugate (ADC) NBE-002 in patients with solid tumors.
- Source: FierceBiotech
- 654
- June 29, 2018
biotech cancer Company Insight
3 Amazing (and Real) Medical Inventions!

Saving lives through accurate diagnosis followed by swift treatment is the major outcome of new and pioneering medical inventions and technologies. And it is encouraging to see that the healthcare industry is heading towards this goal. With this in mind, we have listed three medical advances which have helped to change the medical scenario throughout the world.
- Source: News 24
- 2,145
- June 29, 2018
digital health Market Views medical device
Carisma Therapeutics Bags $53 Million in Series A Funding led by AbbVie

Philadelphia-based Carisma Therapeutics bagged $53 million in series A funding, led by AbbVie Ventures Co-led by HealthCap, new backers Wellington Partners, MRL Ventures Fund, TPG Biotech, and Agent Capital.
- Source: FierceBiotech
- 721
- June 28, 2018
biotech CAR-T therapies Company Insights funding
Celgene Collaboration with Skyhawk for Drug Discovery against Neurological Diseases

To develop small molecules which can target RNA mis-splicing in neurological diseases, Celgene is launching a $60 million collaboration with Skyhawk Therapeutics. Celgene received the option to develop up to five drug molecules for correcting neurological diseases such as Huntington’s disease, amyotrophic lateral sclerosis etc. The $60 million payment includes milestones, license fees and royalties.
- Source: FierceBiotech
- 667
- June 28, 2018
cancer Company Insight neurological
Biotech Crinetics Therapeutics Raises $86 million in IPO

The San Diego-based biotech company Crinetics Therapeutics recently raised $86 million in an IPO. Prior to the new funding, the company received $63.5 million in series B funding and will see its lead asset through phase 2.
- Source: FierceBiotech
- 790
- June 26, 2018
biotech Clinical Trials endocrine disorders
Nanobiotix NBTXR3 in Late Phase Clinical Trial

NBTXR3 is composed of crystalline nanoparticles to amplify the efficacy of radiation therapy. The idea is to administer NBTXR3 as intra-tumoral injections before external beam radiation therapy, thereby increasing the antitumor effect, and thus preparing the patient for surgical resection.
- Source: FierceBiotech
- 604
- June 26, 2018
cancer Clinical Trials radiation therapy
AstraZeneca’s Durvalumab Receives Go-Ahead from DCGI to Market in India

Last Friday, pharma giant AstraZeneca announced that it had received the go-ahead from the Drug Controller General of India (DCGI) to import and market durvalumab (ImfinziTM) in India. The receipt of this permission paves the way for the launch of durvalumab (ImfinziTM) in India. Durvalumab which is a patented drug of Astra-Zeneca, received permission in India to provide treatment for patients with unresectable non-small cell lung cancer and metastatic urothelial carcinoma.
- Source: United News of India
- 2,547
- June 26, 2018
AstraZeneca cancer India New Approvals

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.